Saori Abe
@oriabe114.bsky.social
Rheumatologist🇯🇵MD, PhD👩⚕️mom 👦👧
📖Sjogren’s, Lupus, APS, reproductive health, translational research❤︎
📖Sjogren’s, Lupus, APS, reproductive health, translational research❤︎
📣Upcoming webinar announcement
👇Register for 🆓
#APLAR #AYR #webinar
#osteoporosis
🔗 us06web.zoom.us/webinar/regi...
👇Register for 🆓
#APLAR #AYR #webinar
#osteoporosis
🔗 us06web.zoom.us/webinar/regi...
October 17, 2025 at 7:02 AM
📣Upcoming webinar announcement
👇Register for 🆓
#APLAR #AYR #webinar
#osteoporosis
🔗 us06web.zoom.us/webinar/regi...
👇Register for 🆓
#APLAR #AYR #webinar
#osteoporosis
🔗 us06web.zoom.us/webinar/regi...
September 25, 2025 at 11:27 AM
www.sciencedirect.com/science/arti...
🆕 “ERS/EULAR clinical practice guidelines for connective tissue diseases associated interstitial lung disease”📖
#guidelines #ILD #Rheumsky 🫁
🆕 “ERS/EULAR clinical practice guidelines for connective tissue diseases associated interstitial lung disease”📖
#guidelines #ILD #Rheumsky 🫁
September 8, 2025 at 2:44 AM
www.sciencedirect.com/science/arti...
🆕 “ERS/EULAR clinical practice guidelines for connective tissue diseases associated interstitial lung disease”📖
#guidelines #ILD #Rheumsky 🫁
🆕 “ERS/EULAR clinical practice guidelines for connective tissue diseases associated interstitial lung disease”📖
#guidelines #ILD #Rheumsky 🫁
Day3 #aplar25 recap📷
Plenary3
“Human #SLE” Prof V.Pascual
👉Th10=CXCL13-IL10+IL21+CXCR3+PD1+(contains CD38high) and Tph=CXCL13+IL10-IL21+ are both expanded in SLE🩸
👉 Unique Transcriptional Features of Naïve SLE Treg: FCRL3↑TLR5↑
…TLR5 Ligation decreases⬇️ SLE Naive Treg Suppressive Function
#lupus
Plenary3
“Human #SLE” Prof V.Pascual
👉Th10=CXCL13-IL10+IL21+CXCR3+PD1+(contains CD38high) and Tph=CXCL13+IL10-IL21+ are both expanded in SLE🩸
👉 Unique Transcriptional Features of Naïve SLE Treg: FCRL3↑TLR5↑
…TLR5 Ligation decreases⬇️ SLE Naive Treg Suppressive Function
#lupus
September 7, 2025 at 2:11 PM
2️⃣Prof Ellen
“The changing landscape of #RA ”
#arthritis
👉RA begins years before synovitis, with loss of tolerance and autoAb↑.
👉Prevention trials delay(not prevent) disease onset.
👉 Cell types in synovial tissue differ from blood…Can synovial tissue be used as a predictor of Tx response?
#aplar25
“The changing landscape of #RA ”
#arthritis
👉RA begins years before synovitis, with loss of tolerance and autoAb↑.
👉Prevention trials delay(not prevent) disease onset.
👉 Cell types in synovial tissue differ from blood…Can synovial tissue be used as a predictor of Tx response?
#aplar25
September 5, 2025 at 1:52 AM
2️⃣Prof Ellen
“The changing landscape of #RA ”
#arthritis
👉RA begins years before synovitis, with loss of tolerance and autoAb↑.
👉Prevention trials delay(not prevent) disease onset.
👉 Cell types in synovial tissue differ from blood…Can synovial tissue be used as a predictor of Tx response?
#aplar25
“The changing landscape of #RA ”
#arthritis
👉RA begins years before synovitis, with loss of tolerance and autoAb↑.
👉Prevention trials delay(not prevent) disease onset.
👉 Cell types in synovial tissue differ from blood…Can synovial tissue be used as a predictor of Tx response?
#aplar25
Day1 #APLAR25
Plenary1
1️⃣Prof Josef Smolen
“Managing #RA in
2025: Update of #EULAR
recommendations”
👉 Many recommendations of the 2022 remain unchanged.
👉 JAKi continue to be recommended for pts without risk factors, but otherwise same level (phase Il) as bDMARDs
#arthritis #AYR
Plenary1
1️⃣Prof Josef Smolen
“Managing #RA in
2025: Update of #EULAR
recommendations”
👉 Many recommendations of the 2022 remain unchanged.
👉 JAKi continue to be recommended for pts without risk factors, but otherwise same level (phase Il) as bDMARDs
#arthritis #AYR
September 5, 2025 at 1:42 AM
Day1 #APLAR25
Plenary1
1️⃣Prof Josef Smolen
“Managing #RA in
2025: Update of #EULAR
recommendations”
👉 Many recommendations of the 2022 remain unchanged.
👉 JAKi continue to be recommended for pts without risk factors, but otherwise same level (phase Il) as bDMARDs
#arthritis #AYR
Plenary1
1️⃣Prof Josef Smolen
“Managing #RA in
2025: Update of #EULAR
recommendations”
👉 Many recommendations of the 2022 remain unchanged.
👉 JAKi continue to be recommended for pts without risk factors, but otherwise same level (phase Il) as bDMARDs
#arthritis #AYR
How to choose the right treatment??
👉 Personalized, holistic management—based on clinical & pathological assessment, and shared decision-making with the patient.
#lupus #lupusnepheitis
👉 Personalized, holistic management—based on clinical & pathological assessment, and shared decision-making with the patient.
#lupus #lupusnepheitis
September 4, 2025 at 6:44 AM
How to choose the right treatment??
👉 Personalized, holistic management—based on clinical & pathological assessment, and shared decision-making with the patient.
#lupus #lupusnepheitis
👉 Personalized, holistic management—based on clinical & pathological assessment, and shared decision-making with the patient.
#lupus #lupusnepheitis
From the AURORA study:
Exposure to voclosporin was not associated with nephrotoxicity on repeat kidney biopsy after 18 months.
However, monitor for hypertension and CNI-related nephropathy as potential side effects.
#lupus #lupusnephritis
#APLAR25 🦋🫘
Exposure to voclosporin was not associated with nephrotoxicity on repeat kidney biopsy after 18 months.
However, monitor for hypertension and CNI-related nephropathy as potential side effects.
#lupus #lupusnephritis
#APLAR25 🦋🫘
September 4, 2025 at 6:40 AM
From the AURORA study:
Exposure to voclosporin was not associated with nephrotoxicity on repeat kidney biopsy after 18 months.
However, monitor for hypertension and CNI-related nephropathy as potential side effects.
#lupus #lupusnephritis
#APLAR25 🦋🫘
Exposure to voclosporin was not associated with nephrotoxicity on repeat kidney biopsy after 18 months.
However, monitor for hypertension and CNI-related nephropathy as potential side effects.
#lupus #lupusnephritis
#APLAR25 🦋🫘
Just got to #APLAR25❣️
Attending “Updates and Case Studies in #SLE” session 🦋
Opening ceremony coming up in a few hours!
#APLAR25 #lupus #AYR
Attending “Updates and Case Studies in #SLE” session 🦋
Opening ceremony coming up in a few hours!
#APLAR25 #lupus #AYR
September 4, 2025 at 6:31 AM
Just got to #APLAR25❣️
Attending “Updates and Case Studies in #SLE” session 🦋
Opening ceremony coming up in a few hours!
#APLAR25 #lupus #AYR
Attending “Updates and Case Studies in #SLE” session 🦋
Opening ceremony coming up in a few hours!
#APLAR25 #lupus #AYR
I’m happy to share that I’ll give an oral presentation on Day 1 (Sept 6) at Abstract Session 1: Mechanism of Rheumatic Disease, on our latest work on #Sjogrens disease.
I’m also excited to co-host the #AYR Quiz with friends this year!
Join us and test your rheum knowledge — prizes await! 👑
#APLAR25
I’m also excited to co-host the #AYR Quiz with friends this year!
Join us and test your rheum knowledge — prizes await! 👑
#APLAR25
September 3, 2025 at 12:12 PM
Another #AYR event announcement 📣
Join us on Day 2 of #APLAR2025 at the AYR booth!
It’s a great chance to network, make new friends, and just have fun ❣️
Let’s connect and create awesome memories together 💫
#APLAR #youngrheumatologists #JSTAR
Join us on Day 2 of #APLAR2025 at the AYR booth!
It’s a great chance to network, make new friends, and just have fun ❣️
Let’s connect and create awesome memories together 💫
#APLAR #youngrheumatologists #JSTAR
August 19, 2025 at 11:40 AM
Another #AYR event announcement 📣
Join us on Day 2 of #APLAR2025 at the AYR booth!
It’s a great chance to network, make new friends, and just have fun ❣️
Let’s connect and create awesome memories together 💫
#APLAR #youngrheumatologists #JSTAR
Join us on Day 2 of #APLAR2025 at the AYR booth!
It’s a great chance to network, make new friends, and just have fun ❣️
Let’s connect and create awesome memories together 💫
#APLAR #youngrheumatologists #JSTAR
“Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease “
Great news 👏👏👏
#Rheumsky #Sjogren
🔗 www.novartis.com/news/media-r...
Great news 👏👏👏
#Rheumsky #Sjogren
🔗 www.novartis.com/news/media-r...
August 11, 2025 at 5:08 PM
“Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease “
Great news 👏👏👏
#Rheumsky #Sjogren
🔗 www.novartis.com/news/media-r...
Great news 👏👏👏
#Rheumsky #Sjogren
🔗 www.novartis.com/news/media-r...
📣We’re excited to announce the AYR Quiz at #APLAR2025 will be held on Sep 6 (Day 2)! 🎉
Let’s connect and learn together!🤝
さぁ今年の勝者は誰だ🔥！？
See you there 😊👋
#AYR #APLAR #Rheumsky
Let’s connect and learn together!🤝
さぁ今年の勝者は誰だ🔥！？
See you there 😊👋
#AYR #APLAR #Rheumsky
August 6, 2025 at 10:04 AM
📣We’re excited to announce the AYR Quiz at #APLAR2025 will be held on Sep 6 (Day 2)! 🎉
Let’s connect and learn together!🤝
さぁ今年の勝者は誰だ🔥！？
See you there 😊👋
#AYR #APLAR #Rheumsky
Let’s connect and learn together!🤝
さぁ今年の勝者は誰だ🔥！？
See you there 😊👋
#AYR #APLAR #Rheumsky
Today is #WorldSjogrensDay !
#AYR is raising awareness and sharing information across the field of #rheumatology 😊
You can find #AYR accounts on instagram and LinkedIn👇
#APLAR #AYR
🔗LinkedIn linkedin.com/in/aplar-ayr-8…
🔗Instagram @aplar_ayr
#AYR is raising awareness and sharing information across the field of #rheumatology 😊
You can find #AYR accounts on instagram and LinkedIn👇
#APLAR #AYR
🔗LinkedIn linkedin.com/in/aplar-ayr-8…
🔗Instagram @aplar_ayr
July 23, 2025 at 10:37 AM
Today is #WorldSjogrensDay !
#AYR is raising awareness and sharing information across the field of #rheumatology 😊
You can find #AYR accounts on instagram and LinkedIn👇
#APLAR #AYR
🔗LinkedIn linkedin.com/in/aplar-ayr-8…
🔗Instagram @aplar_ayr
#AYR is raising awareness and sharing information across the field of #rheumatology 😊
You can find #AYR accounts on instagram and LinkedIn👇
#APLAR #AYR
🔗LinkedIn linkedin.com/in/aplar-ayr-8…
🔗Instagram @aplar_ayr
📣Happening tomorrow✨
July 23rd is #WorldSjogrensDay 😊
To raise awareness, an exciting webinar hosted by #APLAR will be held tomorrow📺👇
Register🔗 us06web.zoom.us/webinar/regist…#Sjogrene#AYRY#APLARA#JCRCR
July 23rd is #WorldSjogrensDay 😊
To raise awareness, an exciting webinar hosted by #APLAR will be held tomorrow📺👇
Register🔗 us06web.zoom.us/webinar/regist…#Sjogrene#AYRY#APLARA#JCRCR
July 18, 2025 at 2:17 PM
📣Happening tomorrow✨
July 23rd is #WorldSjogrensDay 😊
To raise awareness, an exciting webinar hosted by #APLAR will be held tomorrow📺👇
Register🔗 us06web.zoom.us/webinar/regist…#Sjogrene#AYRY#APLARA#JCRCR
July 23rd is #WorldSjogrensDay 😊
To raise awareness, an exciting webinar hosted by #APLAR will be held tomorrow📺👇
Register🔗 us06web.zoom.us/webinar/regist…#Sjogrene#AYRY#APLARA#JCRCR
📣To ALL #AYR members 📣
We’re having a photo competition❣️
The winner will be celebrated at this year’s APLAR Congress!
Come join us ☺️✨
#Rheumsky #AYR #APLAR2025
#Rheumphoto
We’re having a photo competition❣️
The winner will be celebrated at this year’s APLAR Congress!
Come join us ☺️✨
#Rheumsky #AYR #APLAR2025
#Rheumphoto
July 9, 2025 at 11:46 PM
📣To ALL #AYR members 📣
We’re having a photo competition❣️
The winner will be celebrated at this year’s APLAR Congress!
Come join us ☺️✨
#Rheumsky #AYR #APLAR2025
#Rheumphoto
We’re having a photo competition❣️
The winner will be celebrated at this year’s APLAR Congress!
Come join us ☺️✨
#Rheumsky #AYR #APLAR2025
#Rheumphoto
“Unbiased analysis identified three immunologically distinct groups of patients that were associated with different patterns of histopathology, renal cell infiltrates, urine proteomic profiles, and treatment response at one year.”
This work was presented at #focis2025 ☺️💕 #lupus #lupusnephritis
This work was presented at #focis2025 ☺️💕 #lupus #lupusnephritis
June 29, 2025 at 6:03 AM
“Unbiased analysis identified three immunologically distinct groups of patients that were associated with different patterns of histopathology, renal cell infiltrates, urine proteomic profiles, and treatment response at one year.”
This work was presented at #focis2025 ☺️💕 #lupus #lupusnephritis
This work was presented at #focis2025 ☺️💕 #lupus #lupusnephritis
Day 3 of #FOCIS2025 (and that’s a wrap for me.)
Thank you to everyone who took the time to chat and connect with me.
Knowing how hard everyone is working every day makes me even more grateful for the meaningful conversations at the conference.
Until we meet again 😊👋
#Rheumsky ❤️ #Immunosky
Thank you to everyone who took the time to chat and connect with me.
Knowing how hard everyone is working every day makes me even more grateful for the meaningful conversations at the conference.
Until we meet again 😊👋
#Rheumsky ❤️ #Immunosky
June 27, 2025 at 2:54 AM
Day 3 of #FOCIS2025 (and that’s a wrap for me.)
Thank you to everyone who took the time to chat and connect with me.
Knowing how hard everyone is working every day makes me even more grateful for the meaningful conversations at the conference.
Until we meet again 😊👋
#Rheumsky ❤️ #Immunosky
Thank you to everyone who took the time to chat and connect with me.
Knowing how hard everyone is working every day makes me even more grateful for the meaningful conversations at the conference.
Until we meet again 😊👋
#Rheumsky ❤️ #Immunosky
2️⃣ Common Mechanisms of Autoimmunity
・The role of inflammation and protein modification in triggering autoimmune responses
・Accumulation of Granzyme K+ in autoimmune tissues, activating the full complement cascade
🍷also had a great night with superstars from JSCI 😁🇯🇵
#focis2025
・The role of inflammation and protein modification in triggering autoimmune responses
・Accumulation of Granzyme K+ in autoimmune tissues, activating the full complement cascade
🍷also had a great night with superstars from JSCI 😁🇯🇵
#focis2025
June 25, 2025 at 3:25 AM
2️⃣ Common Mechanisms of Autoimmunity
・The role of inflammation and protein modification in triggering autoimmune responses
・Accumulation of Granzyme K+ in autoimmune tissues, activating the full complement cascade
🍷also had a great night with superstars from JSCI 😁🇯🇵
#focis2025
・The role of inflammation and protein modification in triggering autoimmune responses
・Accumulation of Granzyme K+ in autoimmune tissues, activating the full complement cascade
🍷also had a great night with superstars from JSCI 😁🇯🇵
#focis2025
My Day1 highlights #focis2025
1️⃣ #Lupus genetics
・51% of RALD (RAS-associated autoimmune lymphoproliferative disease) cases met SLICC criteria.
・COPA syndrome can present like lupus, AAV/RA with STING↑ driving immune dysregulation.
・NADPH oxidase and its role in intrinsic B cell regulation of lupus
1️⃣ #Lupus genetics
・51% of RALD (RAS-associated autoimmune lymphoproliferative disease) cases met SLICC criteria.
・COPA syndrome can present like lupus, AAV/RA with STING↑ driving immune dysregulation.
・NADPH oxidase and its role in intrinsic B cell regulation of lupus
June 25, 2025 at 3:22 AM
My Day1 highlights #focis2025
1️⃣ #Lupus genetics
・51% of RALD (RAS-associated autoimmune lymphoproliferative disease) cases met SLICC criteria.
・COPA syndrome can present like lupus, AAV/RA with STING↑ driving immune dysregulation.
・NADPH oxidase and its role in intrinsic B cell regulation of lupus
1️⃣ #Lupus genetics
・51% of RALD (RAS-associated autoimmune lymphoproliferative disease) cases met SLICC criteria.
・COPA syndrome can present like lupus, AAV/RA with STING↑ driving immune dysregulation.
・NADPH oxidase and its role in intrinsic B cell regulation of lupus
June 24, 2025 at 12:08 PM
June 24, 2025 at 2:25 AM